

**IN THE SPECIFICATION**

Amend the specification as follows:

**Page 1, after the Title, insert the following new paragraph:**

The present application is a continuation of U.S. application Serial No. 09/913,525, filed September 12, 2001, which is a 371 U.S. national phase of PCT/FR00/00375, filed 15 February 2000, which designated the U.S., the entire contents of each of which are hereby incorporated by reference.

**Delete the paragraph spanning lines 24-27 of page 4 and insert the following therefor:**

According to another embodiment of the invention, the said first means are liposomes that have correctly presented target receptor(s) on their surface, thus mimicking ~~miming~~ target cells.

**Delete the paragraph spanning lines 12-16 of page 7 and insert the following therefor:**

Remember that according to the invention, the gp120 or gp160 proteins, or the proteins comprising at least the preserved regions of the gp120 or gp160 proteins, are in the natural form, or in a recombinant ~~recombining~~ form, or in a mutated ~~muted~~ form.

**Delete pages 17-19 and insert the following therefor:**

1 - Amplification by PCR of the C-terminal region between the EcoRI site and the TGA for CCR5:

**Bac-CCR5:** add a *Stu*I site (created by degeneration of the genetic code) and an *Xba*I site into this oligonucleotide, for reintegration of the muted fragment into the original plasmide.

The amplified EcoRI-XbaI fragment is cloned in a pUC vector in EcoRI-XbaI and is then sequenced. The muted fragment is then reinserted in the original EcoRI-XbaI plasmide.

The plasmide thus modified is cut by *Stu*I and *Xba*I and is then bonded with the *Stu*I-*Xba*I DNA fragment described below. This fragment carries 6 Histidine codons and a Stop TAA codon.

697663

AA TTC-A GGC CTG CAC-CAT-CAC-CAT-CAT-CAC TAA GGATCC T  
 G T CCG GAC GTG-GTA-GTG-GTA-GTA-GTG ATT CCTAGG AGATC  
 (SEQ ID Nos:10 and 11, respectively)

An Eco-RI site is added on the input side to clone oligonucleotides matched in an intermediate pUC vector, and thus to verify the sequence.

#### Modification and cloning of CD4

##### 1 - Sequencing of the C-terminal region of the pGEM-T plasmide containing the CD4 gene:

The C-terminal region of the plasmide is verified by sequencing after a PCR\* step.

##### 2 - Addition of 6 histidine residues in the CD4 C-terminal:

##### 1-Amplification of the Bsu361-Banim region by PCR (in the polylinker)

PCR oligonucleotide:

FOR-CD4:

5' CCT AAGCTG ATG CTG AGC TTG (SEQ ID NO:12) 3'

BAC-CD4:

BamHi PstI

5' CAGT GGATCC AAT GGG GCT GCA GGT CTT CTG (SEQ ID NO:13) 3'

*2-Addition of 6 His codons*

1/2 PstI

1/2 BamHI

GC CCC ATT CAC CAT CAT CAT CAC CAC CAT TTA G (SEQ ID NO:14)

ACGTCG GGG TAA GTG GTA GTA GTG GTG GTA ATT CCTAG (SEQ ID NO:15)

PCR\* type oligonucleotide

**CD4-HIS5**

5' 3'  
GCCCCATTCACCATCATCACCACCATTTAG (SEQ ID NO:21)

**CD4-HIS3**

3' 5'  
ACGTCGGGGTAAGTGGTAGTAGTGGTGGTAATTCCTAG (SEQ ID NO:22)

5' 3'  
GATCCTTAATGGTGGTGATGATGGTGAATGGGGCTGCA (SEQ ID NO:16)

FOR-CD4 CCTAAGCTGATGCTGAGCTTG 40 (SEQ ID NO:17)

BAC-CD4 CAGTGGATCCAATGGGGCTGCAGGTCTTCTG 40 (SEQ ID NO:18)

CD4-HIS5 GCCCCATTCACCATCATCACCACCATTAG 40 (SEQ ID NO:19)

CD4-HIS3 GATCCTTAATGGTGGTGATGATGGTGAATGGGGCTGCA 40 (SEQ ID  
NO:20)

**Delete pages 29-38.**

**Insert the attached Sequence Listing, after the claims pages.**